Thomas F Oppelt (Thomas Oppelt)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Coronavirus Disease

Clinical Practice

Drug Administration

Top Venues

Journal of comparative effectiveness research

Infectious diseases and therapy

Journal of racial and ethnic health disparities

This page only lists publications with an associated author ORCID identifier.

Publications

Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Andre C Kalil, Vishnudas Sarda, Celine Der-Torossian, Thomas F Oppelt, Mark C Berry, Alpesh N Amin
Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study. Journal of comparative effectiveness research 13 (4) (2024)
Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Andre C Kalil, Vishnudas Sarda, Celine Der-Torossian, Thomas F Oppelt, Mark C Berry, Alpesh N Amin
Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study. Journal of comparative effectiveness research 13 (4) (2024)
Patrick O Godwin, Bryan Polsonetti, Michael F Caron, Thomas F Oppelt
Remdesivir for the Treatment of COVID-19: A Narrative Review. Infectious diseases and therapy 13 (1) (2024)
Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Andre C Kalil, Vishnudas Sarda, Celine Der-Torossian, Thomas F Oppelt, Mark C Berry, Alpesh N Amin
Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study. Journal of comparative effectiveness research 13 (4) (2024)
Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Andre C Kalil, Vishnudas Sarda, Celine Der-Torossian, Thomas F Oppelt, Mark C Berry, Alpesh N Amin
Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study. Journal of comparative effectiveness research (2024)
Patrick O Godwin, Bryan Polsonetti, Michael F Caron, Thomas F Oppelt
Remdesivir for the Treatment of COVID-19: A Narrative Review. Infectious diseases and therapy (2024)
Patrick O Godwin, Bryan Polsonetti, Michael F Caron, Thomas F Oppelt
Remdesivir for the Treatment of COVID-19: A Narrative Review. Infectious diseases and therapy 13 (1) (2024)
Patrick O Godwin, Bryan Polsonetti, Michael F Caron, Thomas F Oppelt
Remdesivir for the Treatment of COVID-19: A Narrative Review. Infectious diseases and therapy 13 (1) (2024)
Patrick O Godwin, Bryan Polsonetti, Michael F Caron, Thomas F Oppelt
Remdesivir for the Treatment of COVID-19: A Narrative Review. Infectious diseases and therapy 13 (1) (2024)
Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Andre C Kalil, Vishnudas Sarda, Celine Der-Torossian, Thomas F Oppelt, Mark C Berry, Alpesh N Amin
Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study. Journal of comparative effectiveness research 13 (4) (2024)
Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Andre C Kalil, Vishnudas Sarda, Celine Der-Torossian, Thomas F Oppelt, Mark C Berry, Alpesh N Amin
Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study. Journal of comparative effectiveness research 13 (4) (2024)
Thomas F Oppelt, Bryan Polsonetti, Michael F Caron, Carol Collins-Carriveau, Nils Fischer, Larisa Gofman, Marya Ghazipura
Patient Perceptions of their COVID-19 Inpatient Hospital Experience: a Survey Exploring Inequities in Healthcare Delivery. Journal of racial and ethnic health disparities (2022)